目的探讨胆管癌患者血清肿瘤标志物糖类抗原CA19-9水平及其与临床特征的关系,评价其在疾病进展及疗效观察中的意义。方法采用全自动化学发光免疫分析仪测定2009年10月～2011年10月52例确诊初治的胆管癌患者的血清CA19-9水平,观察不同临床分期胆管癌患者CA19-9水平,并与50例健康对照及50例胆道良性疾病患者相比较,分析CA19-9水平与临床特征及临床分期的关系。结果胆管癌组患者血清CA19-9水平为(284.3±62.2)U/ml,明显高于健康对照组的(18.5±6.3)U/ml和胆道良性疾病患者的(94.4±5.5)U/ml,差异有统计学意义(P﹤0.05)。不同临床分期胆管癌患者血清CA19-9水平I期为(124.6±51.2)U/ml,Ⅱ～Ⅲ期为(308.2±65.3)U/ml,Ⅳ期为(354.7±68.5)U/ml,I期与Ⅱ～Ⅲ期及Ⅳ期比较,差异有统计学意义(P﹤0.05),Ⅱ～Ⅲ期与Ⅳ期比较,差异无统计学意义(P﹥0.05)。结论血清CA19-9检测对胆道癌的筛查以及临床分期有一定的价值,对CA19-9水平进行动态检测或肿瘤标志物联合检测有助于进一步明确诊断。 Objective To investigate the relationship between CA19-9, a serum tumor marker in patients with cholangiocarcinoma and its clinical features, and to evaluate its significance in the progression of disease and its therapeutic effect. Methods The level of serum CA19-9 in 52 patients with newly diagnosed cholangiocarcinoma from October 2009 to October 2011 was determined by using the automatic chemiluminescence immunoassay analyzer. The levels of CA19-9 in patients with different clinical stages of cholangiocarcinoma were observed and compared with 50 Cases of healthy controls and 50 cases of benign biliary disease patients compared CA19-9 levels and clinical features and clinical stage of the relationship. Results The level of serum CA19-9 in patients with cholangiocarcinoma was (284.3 ± 62.2) U / ml, which was significantly higher than that in healthy controls (18.5 ± 6.3) U / ml and patients with benign biliary diseases (94.4 ± 5.5) U / ml, The difference was statistically significant (P <0.05). The serum levels of CA19-9 in patients with different clinical stages of cholangiocarcinoma were (124.6 ± 51.2) U / ml, (308.2 ± 65.3) U / ml in stage Ⅱ ~ Ⅲ, 354.7 ± 68.5 U / ml in stage Ⅳ (P <0.05). There was no significant difference between stage Ⅱ ~ Ⅲ and stage Ⅳ (P> 0.05). Conclusion Serum CA19-9 test has certain value in the screening and clinical stage of biliary tract cancer. The dynamic detection of CA19-9 or the joint detection of tumor markers will be helpful to further confirm the diagnosis.